RAF265

• UNSPSC Description:

  RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.

• Target Antigen:

  Apoptosis; Autophagy; Raf; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/RAF265.html

• Purity:

  99.80

• Solubility:

  DMSO : ≥ 26 mg/mL|Ethanol : 10 mg/mL (ultrasonic)

• Smiles:

  FC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F

• Molecular Weight:

  518.41

• References & Citations:

  [1]Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9(2):358-68.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  927880-90-8